FindTrial
Sign In

a study to Compare the efficacy of combination of Fractional CO2 laser with Intralesional Steroid injection against Intralesional Steroid injection alone in the treatment of keloids and hypertrophic scars

Comparative efficacy of combination of Fractional CO2 laser with Intralesional Steroid against Intralesional Steroid alone in the treatment of keloids and hypertrophic scars - An open label randomised control study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048755
Enrollment
60
Registered
2023-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L730- Acne keloid Health Condition 2: L910- Hypertrophic scar

Interventions

Intervention1: Intralesional injection of triamcinolone acetonide 40mg/ml in a dilution of 1:1 with lignocaine followed by a session of fractional CO2 laser: SESSION OF ILS: Administration of injectio

Sponsors

Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of keloid and HTS caused after burns/trauma/surgery. Age 18-55 years having single or multiple keloids/HTS. Size between 3-10 cm.

Exclusion criteria

Exclusion criteria: Patients having keloid/HTS on face/ear lobes. Pregnant or lactating females. History of local/systemic treatment for keloid/HTS in the past 6 months. Signs of active local infections or signs of systemic infection like fever(temp >370C) History of uncontrolled diabetes, hypertension, cardiovascular disorders, bleeding dyscrasias. On anticoagulant therapy. Receiving ultraviolet therapy or radiotherapy at the same site.

Design outcomes

Primary

MeasureTime frame
percentage reduction in length ,breadth and height parameters of keloids and hypertrophic scarsTimepoint: at 16 weeks from baseline in both the arms—

Secondary

MeasureTime frame
percentage reduction in erythema and induration scores, proportion of patients showing patient satisfaction score of more than 6,proportion of patients showing adverse effectsTimepoint: at 16 weeks from baseline.—

Countries

India

Contacts

Public ContactTwinkle Yadav

Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital

vibhumendiratta@rediffmail.com9871016304

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026